July 22, 2020
RealView Imaging Completes Series C Funding Round
July 22, 2020–RealView Imaging Ltd., an Israel-based company developing technology for holography-guided minimally invasive interventions, announced the completion of a $10 million Series C financing round. New investors in this round include OurCrowd, a high-tech venture capital fund; Judith Richter, PhD; Kobi Richter, PhD; and other investors and leading physicians. The majority of the company’s existing shareholders have also participated in this round.
The company’s Holoscope-i is an over-the-head holographic system that creates digital three-dimensional(3D) volumetric holograms from medical imaging data. The system is designed to enable physicians to view and directly interact with hyper-realistic 3D holograms of the patient’s actual anatomy; the holograms float in free space at hands reach during interventional procedures.
In 2019, the company unveiled its first installation of the Holoscope-i commercial configuration at Toronto General Hospital in Toronto, Ontario, where physicians used true holographic imaging during interventional cardiology procedures.
RealView, in collaboration with Philips Healthcare and Schneider Children’s Medical Center in Petah Tikva, Israel, conducted the first clinical study to evaluate the feasibility of live 3D holographic imaging in a clinical setting.
“We are now focused on the commercialization of the Holoscope-i system, initially in North America and in Europe,” commented RealView’s Chairman of the Board, Shimon Eckhouse, PhD, in the company’s announcement. “By incorporating medical holography into routine clinical workflow, we expect to revolutionize the way clinicians engage with 3D medical imaging.”
The company’s next-generation Holoscope, which is currently under development, projects 3D holographic images inside the patient’s body, making the patient “transparent” to enable precise minimally invasive interventional procedures.
As part of the closing, Dr. Kobi Richter, who is Founder and Chairman of Medinol, and Professor Michael Eldar, MD, joined the company’s Board of Directors.
Dr. Richter commented in the press release, “RealView has created a unique solution that will address fundamental usability requirements and a wide range of clinical needs for advanced imaging. Given the company’s broad intellectual property portfolio and technology maturity, I believe RealView can significantly impact the growing field of structural heart interventions, as well as additional future clinical fields such as electrophysiology and interventional oncology procedures. All these fields strongly rely on advanced 3D imaging technologies that will guide the physician accurately and clearly in his intervention in patient spaces that are not visible to his eyes.”